Randomized Trial of Biosimilar XSB-001 Versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
OPHTHALMOLOGY RETINA(2023)
Key words
Biosimilar,Lucentis,Neovascular age-related macular degeneration,Ranibizumab,XSB-001
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined